Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men

Trial Profile

Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Bimatoprost (Primary)
  • Indications Alopecia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Allergan
  • Most Recent Events

    • 15 Mar 2017 Status changed from recruiting to discontinued.
    • 22 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.
    • 22 Sep 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top